Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Matthew C Foster, MD, Yuri Fedoriw, MD, Will Pulley, BA, Joshua Zeidner, MD, Catherine C. Coombs, MD, Emily Mirkin, Maryam Zomorrodi, Rachel Toughiri, PhD, Alena Bartakova, MD, Craig Carson, PhD, Rolf Muller, PhD, Paul M. Armistead, MD PhD

Blood (2019) 134 (Supplement_1): 1417.

https://doi.org/10.1182/blood-2019-127434

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Lindsey E. Roeker, MD, Jennifer R. Brown, MD PhD, Peter Dreger, Oscar B Lahoud, MD, Toby A. Eyre, MBBChir, MRCP, Danielle M. Brander, MD, Alan Skarbnik, MD, Catherine C. Coombs, MD, Haesook T. Kim, PhD, Steven T Manchini, BS, Timothy J Voorhees, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Harriet S Walter, Arvind K. Arumainathan, FRCPath, MBBS, MRCP,, Andrea Sitlinger, MD, Craig S. Sauter, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 3321.

https://doi.org/10.1182/blood-2019-124140

Published: 2019

Journal Articles

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Rebecca Valentin, MD, Jing Deng, PhD, Elisa Ten Hacken, PhD, Timothy Z. Lehmberg, BA, Silvia Buonamici, PhD, Donna S. Neuberg, ScD, Catherine J. Wu, MD, Anthony Letai, MD PhD, Matthew S. Davids, MD MMSc

Blood (2017) 130 (Supplement 1): 4289.

https://doi.org/10.1182/blood.V130.Suppl_1.4289.4289

Published: 2017

Journal Articles

Germline Tissues and DNA Sequencing Analysis Methods for Optimal Somatic Variant Detection in Myelodysplastic Syndrome (MDS)

Eric Padron, MD, Jamie Teer, PhD, Markus Christian Ball, PhD, Jeffrey S Painter, BS, Rami S. Komrokji, MD, Ling Zhang, MD, Lynn C. Moscinski, MD, Mikkael A. Sekeres, MD MS, Steven D. Gore, MD, Rafael Bejar, MD PhD, Matthew J. Walter, MD, Pearlie Epling-Burnette, PhD PharmD

Blood (2017) 130 (Supplement 1): 1685.

https://doi.org/10.1182/blood.V130.Suppl_1.1685.1685

Published: 2017

Journal Articles

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

Blood (2017) 130 (Supplement 1): 1212.

https://doi.org/10.1182/blood.V130.Suppl_1.1212.1212

Published: 2017

Journal Articles

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Stanley Chun-Wei Lee, PhD, Khrystyna Dilai, Esther A. Obeng, MDPhD, Eunhee Kim, PhD, Jean-Baptiste Micol, MD PhD, Akihide Yoshimi, MD PhD, Christophe Willekens, MD, Daichi Inoue, Véronique Saada, PharmD, Hana Cho, Young Rock Chung, MS, James Palacino, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Peter Smith, Benjamin L. Ebert, MD PhD, Robert Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 961.

https://doi.org/10.1182/blood.V128.22.961.961

Published: 2016

Journal Articles

A Chemical Modifier Screen in Zebrafish Mutants for the Spliceosomal Component Sf3b1reveals Genotype-Selective Vulnerabilities

Rosannah C. Cameron, PhD, Mia McKinstry, Adriana De La Garza, Sara Nik, Peter G Smith, PhD, Silvia Buonamici, PhD, Robert K. Bradley, PhD, Teresa V. Bowman, PhD

Blood (2016) 128 (22): 965.

https://doi.org/10.1182/blood.V128.22.965.965

Published: 2016

Journal Articles

Blood ’s 70th anniversary: a rich history

Bob Löwenberg

Blood (2015) 126 (24): 2529–2530.

https://doi.org/10.1182/blood-2015-10-673954

Published: 2015

Journal Articles

Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression

Albert Perez-Ladaga, PhD, Huafeng Xie, PhD, Stuart H. Orkin, MD, David B. Sykes, MD PhD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MDPhD

Blood (2015) 126 (23): 4112.

https://doi.org/10.1182/blood.V126.23.4112.4112

Published: 2015

Journal Articles

A Novel Conditional Knockout of the Diamond Blackfan Anemia Gene Rpl11 Shows Failure of Erythropoiesis, a Marked Increase in BFU-E Progenitors By Phenotype That Proliferate Poorly in Culture, and Activation of p53 Target Genes

Cailin E Joyce, PhD, Meaghan McGuinness, BS, Rebekka K Schneider, MD, Mark D. Fleming, MD DPhil, Dean R Campagna, BS, Paul J Schmidt, PhD, Benjamin L Ebert, MD PhD, Carl D. Novina, MDPhD, Colin A. Sieff, MB.BCh

Blood (2015) 126 (23): 1205.

https://doi.org/10.1182/blood.V126.23.1205.1205

Published: 2015

Journal Articles

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Eunhee Kim, PhD, Janine O. Ilagan, PhD, Stanley Lee, PhD, Aravind Ramakrishnan, MD, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Michele E. Murphy, Min-Kyung Kim, BS, Ahmad S. Zebari, Jacob Feala, Silvia Buonamici, PhD, Peter G Smith, PhD, H. Joachim Deeg, MD, Camille Lobry, PhD, Iannis Aifantis, PhD MSC, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 824.

https://doi.org/10.1182/blood.V124.21.824.824

Published: 2014

Journal Articles

Genomics in 2K10: Fulfilling the Promise of a Sequenced Human Genome

Eric D. Green, MD, PhD

Blood (2010) 116 (21): SCI-16.

https://doi.org/10.1182/blood.V116.21.SCI-16.SCI-16

Published: 2010

Journal Articles

Quantification of Foetal Cells In Foetal Maternal Haemorrhage (FMH): Comparison of 3 Methods

Joyce Overfield, and Pei, MPhil, CSci, Lun Karen Lim, BSc

Blood (2010) 116 (21): 4406.

https://doi.org/10.1182/blood.V116.21.4406.4406

Published: 2010

Journal Articles

Mitochondrial Physiology in Health and Disease: Changes with Aging.

Douglas C. Wallace, PHD

Blood (2009) 114 (22): SCI-1.

https://doi.org/10.1182/blood.V114.22.SCI-1.SCI-1

Published: 2009

NARROW

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Germline Tissues and DNA Sequencing Analysis Methods for Optimal Somatic Variant Detection in Myelodysplastic Syndrome (MDS)

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

A Chemical Modifier Screen in Zebrafish Mutants for the Spliceosomal Component Sf3b1reveals Genotype-Selective Vulnerabilities

Blood ’s 70th anniversary: a rich history

Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression

A Novel Conditional Knockout of the Diamond Blackfan Anemia Gene Rpl11 Shows Failure of Erythropoiesis, a Marked Increase in BFU-E Progenitors By Phenotype That Proliferate Poorly in Culture, and Activation of p53 Target Genes

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Genomics in 2K10: Fulfilling the Promise of a Sequenced Human Genome

Quantification of Foetal Cells In Foetal Maternal Haemorrhage (FMH): Comparison of 3 Methods

Mitochondrial Physiology in Health and Disease: Changes with Aging.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only